Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 168

1.

Plasma concentrations of maraviroc and raltegravir after dual therapy in patients with long-term suppressed viraemia: ROCnRAL ANRS 157 study.

Lê MP, Soulié C, Assoumou L, Valantin MA, Duvivier C, Chas J, Ponscarme D, Marcelin AG, Calvez V, Katlama C, Peytavin G; ROCnRAL ANRS 157 Study Group.

J Antimicrob Chemother. 2015 Apr 26. pii: dkv113. [Epub ahead of print] No abstract available.

PMID:
25917348
2.

Dolutegravir in HIV-2-Infected Patients With Resistant Virus to First-line Integrase Inhibitors From the French Named Patient Program.

Descamps D, Peytavin G, Visseaux B, Tubiana R, Damond F, Campa P, Charpentier C, Khuong-Josses MA, Duvivier C, Karmochkine M, Lukiana T, Matheron S.

Clin Infect Dis. 2015 May 15;60(10):1521-7. doi: 10.1093/cid/civ124. Epub 2015 Feb 17.

PMID:
25690598
3.

Non-virological response to a dolutegravir-containing regimen in a patient harbouring a E157Q-mutated virus in the integrase region.

Danion F, Belissa E, Peytavin G, Thierry E, Lanternier F, Scemla A, Lortholary O, Delelis O, Avettand-Fenoel V, Duvivier C.

J Antimicrob Chemother. 2015 Jun;70(6):1921-3. doi: 10.1093/jac/dkv012. Epub 2015 Feb 10. No abstract available.

PMID:
25670643
4.

Claudin-1 gene variants and susceptibility to hepatitis C infection in HIV-1 infected intravenous drug users (an ANRS case-control study).

Ghosn J, Fouquet B, Quertainmont Y, Salmon D, Sahali S, Rioux C, Duvivier C, Mole M, Delfraissy JF, Misrahi M.

J Med Virol. 2015 Apr;87(4):619-24. doi: 10.1002/jmv.24088. Epub 2015 Jan 21.

PMID:
25611191
5.

Efficacy and tolerability of Etravirine in HIV-1 adult patients: Results of a large French prospective cohort.

Allavena C, Katlama C, Cotte L, Roger PM, Delobel P, Cheret A, Duvivier C, Poizot-Martin I, Hoen B, Cabié A, Cheret A, Lahoulou R, Raffi F, Pugliese P.

J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19780. doi: 10.7448/IAS.17.4.19780. eCollection 2014.

6.

Cohort Profile: French hospital database on HIV (FHDH-ANRS CO4).

Mary-Krause M, Grabar S, Lièvre L, Abgrall S, Billaud E, Boué F, Boyer L, Cabié A, Cotte L, De Truchis P, Duval X, Duvivier C, Enel P, Gasnault J, Gaud C, Gilquin J, Guiguet M, Katlama C, Khuong-Josses MA, Lacombe JM, Lang S, Lascaux AS, Launay O, Mahamat A, Matheron S, Meynard JL, Pavie J, Pilorgé F, Piroth L, Poizot-Martin I, Potard V, Pradier C, Reynes J, Rouveix E, Selinger-Leneman H, Simon A, Tattevin P, Tissot-Dupont H, Viard JP, Viget N, Costagliola D.

Int J Epidemiol. 2014 Oct;43(5):1425-36. doi: 10.1093/ije/dyu002. Epub 2014 Feb 17.

PMID:
24550249
7.

Maraviroc plus raltegravir failed to maintain virological suppression in HIV-infected patients with lipohypertrophy: results from the ROCnRAL ANRS 157 study.

Katlama C, Assoumou L, Valantin MA, Soulié C, Duvivier C, Chablais L, Kolta S, Pialoux G, Mercié P, Simon A, Costagliola D, Peytavin G, Marcelin AG; ROCnRAL ANRS 157 Study Group.

J Antimicrob Chemother. 2014 Jun;69(6):1648-52. doi: 10.1093/jac/dkt536. Epub 2014 Feb 16.

8.

Correlates of HIV sustained viral suppression in HIV/hepatitis C virus coinfected patients: possible role of the hepatitis C virus sustained viral response.

Bani-Sadr F, Loko MA, Pambrun E, Winnock M, Carrieri P, Gilbert C, Duvivier C, Bouchaud O, Gervais A, Dabis F, Salmon D; ANRS CO 13 HEPAVIH Study Group.

AIDS. 2014 May 15;28(8):1155-60. doi: 10.1097/QAD.0000000000000218.

PMID:
24499953
9.

Frequency dependence of capnography in anesthetized rabbits.

Ioan I, Demoulin B, Duvivier C, Leblanc AL, Bonabel C, Marchal F, Schweitzer C, Varechova S.

Respir Physiol Neurobiol. 2014 Jan 1;190:14-9. doi: 10.1016/j.resp.2013.09.002. Epub 2013 Sep 12.

PMID:
24035836
10.

A single HIV-1 cluster and a skewed immune homeostasis drive the early spread of HIV among resting CD4+ cell subsets within one month post-infection.

Bacchus C, Cheret A, Avettand-Fenoël V, Nembot G, Mélard A, Blanc C, Lascoux-Combe C, Slama L, Allegre T, Allavena C, Yazdanpanah Y, Duvivier C, Katlama C, Goujard C, Seksik BC, Leplatois A, Molina JM, Meyer L, Autran B, Rouzioux C; OPTIPRIM ANRS 147 study group.

PLoS One. 2013 May 14;8(5):e64219. doi: 10.1371/journal.pone.0064219. Print 2013.

11.

[Value of the Linton-Nachlas balloon for the management of post-partum hemorrhage: a series of 25 cases].

Florian A, Carles G, Dallah F, Ibrahim N, Alassas N, Duvivier C.

J Gynecol Obstet Biol Reprod (Paris). 2013 Sep;42(5):493-8. doi: 10.1016/j.jgyn.2013.02.008. Epub 2013 Apr 6. French.

12.

Efficacy, safety, and pharmacokinetics of once-daily boosted darunavir in pretreated HIV-infected patients.

Zucman D, De Truchis P, Peytavin G, Descamps D, Duvivier C, Tegna L, Weiss L, Delassus JL, Benalycherif A, Landman R.

Scand J Infect Dis. 2013 May;45(5):407-10. doi: 10.3109/00365548.2012.751507. Epub 2013 Mar 11.

PMID:
23477545
13.

Prevalence of CXCR4-tropic viruses in clustered transmission chains at the time of primary HIV-1 infection.

Frange P, Meyer L, Ghosn J, Deveau C, Goujard C, Duvivier C, Tubiana R, Rouzioux C, Chaix ML; ANRS CO6 PRIMO Cohort Study Group.

Clin Microbiol Infect. 2013 May;19(5):E252-5. doi: 10.1111/1469-0691.12127. Epub 2013 Jan 17.

14.

Incidence of HIV-related anal cancer remains increased despite long-term combined antiretroviral treatment: results from the french hospital database on HIV.

Piketty C, Selinger-Leneman H, Bouvier AM, Belot A, Mary-Krause M, Duvivier C, Bonmarchand M, Abramowitz L, Costagliola D, Grabar S.

J Clin Oncol. 2012 Dec 10;30(35):4360-6. doi: 10.1200/JCO.2012.44.5486. Epub 2012 Oct 22.

15.

Switching to darunavir/ritonavir 800/100 mg once-daily containing regimen maintains virological control in fully suppressed pre-treated patients infected with HIV-1.

Ghosn J, Slama L, Chermak A, Houssaini A, Lambert-Niclot S, Schneider L, Fourn E, Duvivier C, Simon A, Courbon E, Murphy R, Flandre P, Peytavin G, Katlama C; RADAR Study Group.

J Med Virol. 2013 Jan;85(1):8-15. doi: 10.1002/jmv.23404. Epub 2012 Sep 28.

PMID:
23024008
16.

Boosted protease inhibitor monotherapy as a maintenance strategy: an observational study.

Guiguet M, Ghosn J, Duvivier C, Meynard JL, Gras G, Partisani M, Teicher E, Mahamat A, Rodenbourg F, Launay O, Costagliola D; FHDH-ANRS CO4.

AIDS. 2012 Nov 28;26(18):2345-50. doi: 10.1097/QAD.0b013e32835646e0.

PMID:
22695301
17.

High frequency of vitamin D deficiency in HIV-infected patients: effects of HIV-related factors and antiretroviral drugs.

Allavena C, Delpierre C, Cuzin L, Rey D, Viget N, Bernard J, Guillot P, Duvivier C, Billaud E, Raffi F.

J Antimicrob Chemother. 2012 Sep;67(9):2222-30. doi: 10.1093/jac/dks176. Epub 2012 May 15.

18.

Lipid profiles for etravirine versus efavirenz in treatment-naive patients in the randomized, double-blind SENSE trial.

Fätkenheuer G, Duvivier C, Rieger A, Durant J, Rey D, Schmidt W, Hill A, van Delft Y, Marks S; SENSE Study Team.

J Antimicrob Chemother. 2012 Mar;67(3):685-90. doi: 10.1093/jac/dkr533. Epub 2011 Dec 29.

19.

Factors associated with virological failure in HIV-1-infected patients receiving darunavir/ritonavir monotherapy.

Lambert-Niclot S, Flandre P, Valantin MA, Peytavin G, Duvivier C, Haim-Boukobza S, Algarte-Genin M, Yazdanpanah Y, Girard PM, Katlama C, Calvez V, Marcelin AG.

J Infect Dis. 2011 Oct 15;204(8):1211-6. doi: 10.1093/infdis/jir518.

20.

Phase 2 double-blind, randomized trial of etravirine versus efavirenz in treatment-naive patients: 48-week results.

Gazzard B, Duvivier C, Zagler C, Castagna A, Hill A, van Delft Y, Marks S.

AIDS. 2011 Nov 28;25(18):2249-58. doi: 10.1097/QAD.0b013e32834c4c06.

PMID:
21881478
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk